Switching to Fixed-Dose Bictegravir, Emtricitabine, and Tenofovir Alafenamide (B/F/TAF) in Virologically Suppressed HIV-1 Infected Women: A Randomized, Open-Label, Multicenter, Active-Controlled, Phase 3, Noninferiority Trial
| Autor: | Ploenchan Chetchotisakd, Cissy Kityo, Khuanchai Supparatpinyo, Anchalee Avihingsanon, Evgeny Voronin, Tariro Makadzange, Huyen Cao, Jeffrey L. Stephens, Rima Acosta, Edwin DeJesus, Vadim Pokrovsky, Natalya Gankina, Erin Quirk, Ellen Koenig, Hal Martin, Hui Wang, Debbie Hagins |
|---|---|
| Přispěvatelé: | Global Health, Graduate School, AII - Infectious diseases, APH - Personalized Medicine, APH - Quality of Care |
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Adult
Male Oncology medicine.medical_specialty Anti-HIV Agents Pyridones Human immunodeficiency virus (HIV) HIV Infections 030312 virology medicine.disease_cause Emtricitabine Heterocyclic Compounds 4 or More Rings Tenofovir alafenamide Piperazines law.invention Young Adult 03 medical and health sciences Randomized controlled trial law Internal medicine Humans Medicine Pharmacology (medical) Tenofovir 0303 health sciences Alanine Bictegravir business.industry Adenine virus diseases Middle Aged Amides CD4 Lymphocyte Count Clinical trial Treatment Outcome Infectious Diseases Tolerability HIV-1 Female Open label business Heterocyclic Compounds 3-Ring medicine.drug |
| Zdroj: | Journal of acquired immune deficiency syndromes (1999), 82(3), 321-328. Lippincott Williams and Wilkins |
| ISSN: | 1525-4135 |
| Popis: | BACKGROUND: Bictegravir, coformulated with emtricitabine/tenofovir alafenamide as a fixed-dose combination (B/F/TAF), is recommended for treatment of HIV-1-infection. Multiple studies of B/F/TAF in treatment-naive and virologically suppressed cohorts have shown high efficacy and tolerability with no treatment-emergent resistance through 48 weeks. Participants in these studies have been predominantly men. We report 48-week results from a phase 3 study evaluating switching to B/F/TAF, specifically in a globally distributed trial population of women. METHODS: In this multicenter, randomized, open-label, active-controlled, noninferiority trial (ClinicalTrials.gov NCT02652624), women living with HIV who were virologically suppressed (HIV-1 RNA levels |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|